<DOC>
	<DOCNO>NCT01551641</DOCNO>
	<brief_summary>The purpose study down-regulate VEGF expression esophageal cancer patient thalidomide , improve chemoradiotherapy effect . Patients esophageal cancer receive chemoradiotherapy divide different sub-group accord dynamic change VEGF level , show increase unchanged VEGF add thalidomide random . Efficacy side effect thalidomide combine chemoradiotherapy evaluate , time , activity thalidomide esophageal cancer clinical safely assess .</brief_summary>
	<brief_title>Phase II Trial Thalidomide Combined With Concurrent Chemoradiotherapy Esophageal Cancer</brief_title>
	<detailed_description>Radiotherapy : Patients conduct CT simulation , three-dimensional conformal radiation therapy ( 3DCRT ) perform . 1.8-2.0 Gy/fraction , 5 fraction week , total dose 60-72Gy delivered patient 6-MV-X-ray linear accelerator . Chemotherapy : Patients concurrently administer irradiation every 4 week PT regimen ( cis-platinum 25 mg/m2/d , d1-4 ; PTX ( paclitaxel ) 135mg/m2/d , d1 ) 4 cycle . For first 2-cycles chemotherapy concurrently give irradiation remain 2 cycle , irradiation . Administration thalidomide : Determine serum VEGF level esophageal cancer patient 3-4 week begin radiotherapy , whose VEGF level , compare radiotherapy , increase unchanged divide two group : one give thalidomide concurrent follow chemoradiotherapy , 100mg/d bedtime initial week , moderate side effect occur 200mg/d next week till end chemoradiotherapy ; receive concurrent chemoradiotherapy . VEGF determination : Peripheral venous blood sample take one week , 3-4 week , one week radiotherapy respectively . The serum VEGF determine double antibody sandwich ELISA .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>cytologically histologically confirm esophageal carcinoma age 20 80 Karnofsky performance status ≥ 70 treatment prior enrollment least one measurable lesion CT , MRI esophageal barium exam normal function heart , lung , liver , kidney bone marrow blood exam qualify chemotherapy , include hemoglobulin ≥9 g/dl , neutrophil ≥1.5×109/L platelet ( PLT ) ≥100×109/L , creatinine ≤1.5 UNL inform consent sign prior treatment chemotherapy irradiation poor bone marrow , liver kidney function , would make chemotherapy intolerable contraindication irradiation : complete obstruction esophagus , deep esophageal ulcer , fistula mediastinum , haematemesis participate clinical trial pregnancy , breast feeding , adopt birth control drug alcohol addiction , uncontrolled epileptic seizure , psychotic ability self control coexist morbidity investigator believe suitable chemoradiation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>VEGF</keyword>
	<keyword>Thalidomide</keyword>
</DOC>